| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
524212 Stock Overview
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India.
Wanbury Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹64.05 |
| 52 Week High | ₹111.75 |
| 52 Week Low | ₹55.55 |
| Beta | 0.95 |
| 1 Month Change | -2.21% |
| 3 Month Change | -6.29% |
| 1 Year Change | -21.22% |
| 3 Year Change | 407.13% |
| 5 Year Change | 71.95% |
| Change since IPO | -65.63% |
Recent News & Updates
Shareholder Returns
| 524212 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -7.7% | -0.3% | 0.8% |
| 1Y | -21.2% | -12.0% | 8.3% |
Return vs Industry: 524212 underperformed the Indian Pharmaceuticals industry which returned -12% over the past year.
Return vs Market: 524212 underperformed the Indian Market which returned 8.3% over the past year.
Price Volatility
| 524212 volatility | |
|---|---|
| 524212 Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: 524212 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 524212's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 1,156 | n/a | https://www.wanbury.com |
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India. The company offers formulations for gynecology, orthopedics, heamatinics, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner purposes approximately under 70 brands. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas.
Wanbury Fundamentals Summary
| 524212 fundamental statistics | |
|---|---|
| Market Cap | ₹2.09b |
| Earnings (TTM) | ₹750.90m |
| Revenue (TTM) | ₹5.00b |
2.8x
P/E Ratio0.4x
P/S RatioIs 524212 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524212 income statement (TTM) | |
|---|---|
| Revenue | ₹5.00b |
| Cost of Revenue | ₹3.00b |
| Gross Profit | ₹2.00b |
| Other Expenses | ₹1.25b |
| Earnings | ₹750.90m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 22.97 |
| Gross Margin | 39.99% |
| Net Profit Margin | 15.01% |
| Debt/Equity Ratio | -314.3% |
How did 524212 perform over the long term?
See historical performance and comparisonValuation
Is 524212 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Analyst Forecast
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 524212?
Other financial metrics that can be useful for relative valuation.
| What is 524212's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | ₹2.09b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 0.5x |
| Enterprise Value/EBITDA | 8.9x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does 524212's PE Ratio compare to its peers?
| 524212 PE Ratio vs Peers |
|---|
| Company | PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 20x | ||
JSLL Jeena Sikho Lifecare | 19.3x | n/a | ₹2.2b |
500009 Ambalal Sarabhai Enterprises | 10x | n/a | ₹2.2b |
PAR Par Drugs and Chemicals | 22.5x | n/a | ₹2.0b |
531726 Panchsheel Organics | 28.5x | n/a | ₹2.4b |
524212 Wanbury | 2.8x | n/a | ₹2.1b |
Price-To-Earnings vs Peers: 524212 is good value based on its Price-To-Earnings Ratio (2.8x) compared to the peer average (20x).
Price to Earnings Ratio vs Industry
How does 524212's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 524212 is good value based on its Price-To-Earnings Ratio (2.8x) compared to the Indian Pharmaceuticals industry average (22.6x)
Price to Earnings Ratio vs Fair Ratio
What is 524212's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 2.8x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 524212's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 524212 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 524212 (₹64.05) is trading below our estimate of fair value (₹198.74)
Significantly Below Fair Value: 524212 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Future Growth
How is Wanbury forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
19.1%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wanbury has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine whether Wanbury is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Wanbury competitive advantages and company strategy can generally be found in its financial reports archived here.
Past Performance
How has Wanbury performed over the past 5 years?
Past Performance Score
2/6Past Performance Score 2/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
52.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 524212 has a large one-off gain of ₹763.7M impacting its June 30 2022 financial results.
Growing Profit Margin: 524212 became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: 524212's earnings have grown significantly by 52.4% per year over the past 5 years.
Accelerating Growth: 524212 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 524212 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.3%).
Return on Equity
High ROE: 524212's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Discover strong past performing companies
Financial Health
How is Wanbury's financial position?
Financial Health Score
1/6Financial Health Score 1/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: 524212 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: 524212 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: 524212 has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: 524212's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Debt Coverage: 524212's debt is well covered by operating cash flow (51%).
Interest Coverage: 524212's interest payments on its debt are not well covered by EBIT (0.9x coverage).
Balance Sheet
Discover healthy companies
Dividend
What is Wanbury current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Cash Flow Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 524212's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 524212's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 524212's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 524212's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 524212 has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
6.3yrs
Average management tenure
CEO
Wanbury has no CEO, or we have no data on them.
Leadership Team
Experienced Management: 524212's management team is seasoned and experienced (6.3 years average tenure).
Board Members
Experienced Board: 524212's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Wanbury Limited's employee growth, exchange listings and data sources
Key Information
- Name: Wanbury Limited
- Ticker: 524212
- Exchange: BSE
- Founded: 1988
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹2.094b
- Shares outstanding: 32.70m
- Website: https://www.wanbury.com
Number of Employees
Location
- Wanbury Limited
- BSEL Tech Park, B-Wing
- 10th Floor
- Navi Mumbai
- Maharashtra
- 400703
- India
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/08/16 00:00 |
| End of Day Share Price | 2022/08/16 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2022/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.